Mymd Pharmaceuticals (NASDAQ:QCLS) Shares Down 8% – Should You Sell?

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS)’s share price dropped 8% during mid-day trading on Wednesday. The stock traded as low as $0.3910 and last traded at $0.3910. Approximately 165,870 shares traded hands during trading, a decline of 4% from the average session volume of 173,338 shares. The stock had previously closed at $0.4250.

Wall Street Analysts Forecast Growth

QCLS has been the topic of a number of recent analyst reports. Weiss Ratings cut Mymd Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Thursday, October 29th. Wall Street Zen upgraded Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Mymd Pharmaceuticals Stock Performance

The business has a fifty day moving average price of $0.97. The stock has a market capitalization of $3.20 million, a P/E ratio of -0.11 and a beta of 2.21.

Mymd Pharmaceuticals (NASDAQ:QCLS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.79) EPS for the quarter.

Mymd Pharmaceuticals Company Profile

TNF Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation.